SCHEDULE: Freebird Partners Discloses 9.9% Stake in Ernexa

Freebird Partners LP and affiliates have filed an amended Schedule 13G reporting a 9.9% beneficial ownership stake in Ernexa Therapeutics Inc.

Summary

• Freebird Partners LP, Freebird Investments LLC, and Curtis W. Huff collectively report beneficial ownership of 120,412 shares of Ernexa Therapeutics Inc. common stock.
• The reported ownership represents 9.9% of the issuer's outstanding common stock.
• The holdings include 81,417 shares of common stock, 52,000 shares issuable upon exercise of common warrants, and 15,015 shares issuable upon exercise of pre-funded warrants.
• The reporting persons are subject to a 9.99% beneficial ownership limitation regarding the exercise of their warrants.
• The share counts reflect a 1-for-25 reverse stock split effective May 4, 2026.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral regulatory filing that confirms existing institutional interest without indicating new material developments.

Positives

• The reporting group maintains a significant 9.9% equity position, signaling continued interest in the company's performance.

Negatives

• The filing highlights the existence of warrants with exercise prices as high as $17.00, which may be significantly out-of-the-money depending on current market conditions.

Risks

• The reporting persons are restricted from exercising warrants if such exercise would result in beneficial ownership exceeding 9.99% of the outstanding common stock.
• The company's capital structure includes various classes of warrants that could lead to future dilution for existing shareholders.

Future Outlook

The filing does not provide forward-looking business guidance, as it is a regulatory disclosure of beneficial ownership.

Industry Context

StockSavvy.ai notes that this filing is a standard regulatory update regarding institutional ownership levels in a small-cap biotechnology firm, reflecting typical portfolio management activities rather than a strategic shift in the company's operations.

Comparison to Industry Standards

• The 9.9% ownership threshold is a common benchmark for institutional investors to maintain to avoid triggering more stringent reporting requirements associated with 10% or greater ownership.
• The use of 9.99% ownership blockers in warrant agreements is a standard practice in biotech financing to manage regulatory compliance and avoid 'insider' status under Section 16 of the Exchange Act.

Stakeholder Impact

• Shareholders should note the potential for future dilution if warrants are exercised, though this is currently capped by the 9.99% ownership limitation.

Next Steps

• Continued monitoring of the issuer's share price relative to the $17.00 warrant exercise price.

Key Dates

Keywords

Ernexa Therapeutics, Schedule 13G, Beneficial Ownership, Freebird Partners, Reverse Stock Split, Equity Disclosure